Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
05/2005
05/19/2005WO2005044199A2 Combination of proton pump inhibitor and sleep aid
05/19/2005WO2005044198A2 Process and formulation containing epothilones and analogs thereof
05/19/2005WO2005044197A2 Synthesis of glycopeptides with superior pharmacokinetic properties
05/19/2005WO2005044195A2 Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
05/19/2005WO2005044194A2 TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
05/19/2005WO2005044193A2 Product and process for increasing compactibility of carbohydrates
05/19/2005WO2005044192A2 Triazole compounds and uses related thereto
05/19/2005WO2005044191A2 Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells
05/19/2005WO2005044189A2 Dialysates and methods and systems related thereto
05/19/2005WO2005044188A2 Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
05/19/2005WO2005044187A2 Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
05/19/2005WO2005044186A2 Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
05/19/2005WO2005044185A2 Electromagnetic field regulating compositions
05/19/2005WO2005044183A2 Methods and compositions using adiponectin for treatment of cardiac disorders and for stimulation of angiogenesis
05/19/2005WO2005044182A2 Compositions of botanical extracts for cancer therapy
05/19/2005WO2005044179A2 Formulations containing astragalus extracts and uses thereof
05/19/2005WO2005044178A2 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
05/19/2005WO2005044177A2 Method for producing abrasive non-woven cloth
05/19/2005WO2005044176A2 Compositions containing phosphatidic acid, methods of use thereof, methods of manufacture thereof, and articles of manufacture containing same
05/19/2005WO2005044175A2 Desensitization of complement activation using monocyte/macrophage inhibitory compounds
05/19/2005WO2005043971A2 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
05/19/2005WO2005030140A3 C-met modulators and methods of use
05/19/2005WO2005030128A3 Pyrazole modulators of metabotropic glutamate receptors
05/19/2005WO2005027848A3 Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators
05/19/2005WO2005025517A9 Animal model for protease activity and liver damage
05/19/2005WO2005023185A3 Pharmaceutical compositions and method of using levodopa and carbidopa
05/19/2005WO2005020917A3 Ophthalmic compositions for treating ocular hypertension
05/19/2005WO2005020879A3 Compositions for treating pathologies that necessitate suppression of gastric acid secretion
05/19/2005WO2005018545A3 Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
05/19/2005WO2005018542A3 Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
05/19/2005WO2005016263A3 Compositions and methods for treating hyperimmune response in the eye
05/19/2005WO2005016228A3 Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders
05/19/2005WO2005011613A8 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
05/19/2005WO2005011568A3 Process for extracting vital components from plants
05/19/2005WO2005009346A3 Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
05/19/2005WO2005007105A3 Pharmaceutical compositions
05/19/2005WO2005007079A3 Inactivators and bivalent inhibitors of glyoxalase i and methods of inhibiting tumor growth
05/19/2005WO2005000211A3 Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes
05/19/2005WO2004112711A3 Oral extended-release composition
05/19/2005WO2004112690B1 2-aminobenzoyl derivatives
05/19/2005WO2004110367A3 Sdr proteins from staphylococcus capitis and their use in preventing and treating infections
05/19/2005WO2004108083A3 Methods for the selective treatment of tumors by calcium-mediated induction of apoptosis
05/19/2005WO2004105701B1 Compositions and methods for symptomatic relief
05/19/2005WO2004103279A3 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
05/19/2005WO2004100884A3 Oral care methods and products
05/19/2005WO2004098526A3 Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
05/19/2005WO2004093778A8 Oligonucleotides that block toll-like receptors
05/19/2005WO2004091529B1 Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom
05/19/2005WO2004087063A3 Use of erythropoietin in stroke recovery
05/19/2005WO2004078145B1 Combination therapy with glatiramer acetate and simvastatin for the treatment of multiple sclerosis
05/19/2005WO2004075846A3 Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
05/19/2005WO2004069201A3 Compounds useful in coating stents to prevent and treat stenosis and restenosis
05/19/2005WO2004064776A3 Methods of preparation of live attenuated bacterial vaccines by alteration of dna adenine methylase (dam) activity in those bacteria
05/19/2005WO2004064745A3 Method of preparation of heterocyclic molecules with pharmaceutical pharmaceutical excipient cosmeceutical agrochemical and industrial uses
05/19/2005WO2004064719A3 Synergistic compositions and methods for potentiating anti-oxidative activity
05/19/2005WO2004064718A3 Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
05/19/2005WO2003092592A3 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
05/19/2005WO2003077858A3 Humanized antibodies that recognize beta amyloid peptide
05/19/2005US20050107804 Method and device for umbilicus protection during abdominal surgery
05/19/2005US20050107789 Method for interconnecting longitudinal members extending along a spinal column
05/19/2005US20050107458 used as diagnostic kits, bioassay and/or drugs for preventing cancers, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, Huntington's disease, epilepsy, multiple sclerosis, neuropathy, or injuries of the brain or spinal chord, or as tyrosine kinase inhibitors
05/19/2005US20050107435 antibiotics such as (5S,5S')-N-(3-{4'-[5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2,2'-difluoro-biphenyl-4-yl}-2-oxo-oxazolidin-5-ylmethyl)-acetamide, used for treating a bacterial infections in mammals
05/19/2005US20050107430 inhibiting infections by microorganism or viruses by administering dibenzo[a,g]-fluorenyl and chrysenyl compounds
05/19/2005US20050107418 Macrolides
05/19/2005US20050107387 Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
05/19/2005US20050107386 Methods of treating diseases and disorders by targeting multiple kinases
05/19/2005US20050107385 Aromatic prodrugs of propofol, compositions and uses thereof
05/19/2005US20050107381 e.g. 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-pyridin-2-yl-butyramide; inhibiting A beta -production; Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis, cerebral amyloid angiopathy, a prion-mediated disease, inclusion body myositis, stroke, multiple sclerosis and Down's Syndrome
05/19/2005US20050107368 Inhibitors of cathepsin S
05/19/2005US20050107361 Anticoagulants; improved side effect reduction, pharmacokinetics and bioavailability
05/19/2005US20050107357 2,4-dioxo-3-quinazolinylaryl sulfonylureas
05/19/2005US20050107350 reducing the dosage and unwanted side effects that are present in current treatments; kits
05/19/2005US20050107349 Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith
05/19/2005US20050107346 Synergistic treatment, better effects on solid tumours; with a mixture of a platinum anticancer agents and a taxane, with ionizing radiation therapy
05/19/2005US20050107337 Platinum complexes having antitumor activity
05/19/2005US20050107322 Compositions for inducing immune responses
05/19/2005US20050106727 Peptides for enhanced cell attachment and growth
05/19/2005US20050106275 inhibit, block, and/or prevent metastasis of carcinogenic cells away from a primary cancer site
05/19/2005US20050106248 Extended release venlafaxine formulation
05/19/2005US20050106189 Pharmaceutical formulation comprising cyclosporin and use thereof
05/19/2005US20050106150 Restoring sensitivity to drug resistant tumor cells
05/19/2005US20050106147 Method of promoting graft survival with anti-tissue factor antibodies
05/19/2005US20050106133 Containing lactobacillus; storage stability
05/19/2005US20050106106 In-vivo diagnostic method by near infrared radiation
05/19/2005US20050104606 Systems and methods for measuring tear film osmolarity
05/19/2005CA2544924A1 Methods and compositions for treating mcp-1 related pathologies
05/19/2005CA2544343A1 Electromagnetic field regulating compositions
05/19/2005CA2544235A1 Dialysates and methods and systems related thereto
05/19/2005CA2543602A1 Triazole compounds and uses related thereto
05/19/2005CA2543484A1 Modulation of immune response to an immunogen with ctla-4 and tnfbp
05/19/2005CA2543482A1 Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
05/19/2005CA2543166A1 Ph sensitive prodrugs of 2,6-diisopropylphenol
05/19/2005CA2543164A1 Combination of proton pump inhibitor and sleep aid
05/19/2005CA2543160A1 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
05/19/2005CA2542602A1 Desensitization of complement activation using monocyte/macrophage inhibitory compounds
05/19/2005CA2542142A1 Methods and compositions using adiponectin for treatment of cardiac disorders and for stimulation of angiogenesis
05/19/2005CA2541212A1 Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
05/19/2005CA2538218A1 Compositions of botanical extracts for cancer therapy
05/19/2005CA2537118A1 Composition for topical use containing an extract of stryphnodendron, its preparation and its application
05/18/2005CN1617738A Catheter composition and uses thereof
1 ... 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 ... 295